6 May 2020

NYC Health and Evidation Collaborate with the Icahn School of Medicine at Mount Sinai to Launch Study on COVID-19’s Impact on Mental Health

1 May 2020

How the UK life sciences industry is rising to the challenge of Covid-19 by Kate Bingham

31 March 2020

SV Health Investors Announces Licensing and Research Collaboration between Sitryx and Lilly to Discover and Develop New Immunometabolic Medicines

26 March 2020

SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

• 
  27 April 2020Portfolio News

  Xilio Therapeutics Appoints Martin H. Huber, M.D. as Chief Medical Officer to lead XTX201 (tumor-selective IL-2) and XTX101 (tumor-Selective aCTLA-4) into the clinic while xilio continues to advance its tumor-selective cytokine pipeline

---